QuidelOrtho stock
QDELNASDAQQuidelOrtho Corporation, HealthcareISIN US2197981051
32Score 32 out of 100, Weak
Price and trend
33 / 100
Price history
−53% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 31% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 34).
The price is 70% below its 52-week high. Largest decline in 20 years: 97% (August 2020 to May 2026).
Chart figures for advanced users
- SMA 50$12.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.46
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)34
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.96
- The lowest closing price of the last twelve months.
- Resistance$35.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- QuidelOrtho Corporation belongs to the Medical (Specialties) industry (United States) and, with a market value of $728.67M, is number 8 of 14 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.73B (down 1.9% year on year) and a loss of $1.13B.
- MEQIRI Score 32 out of 100 (Weak): rank 675 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Margin fallingOperating margin −33.7%, average of the prior years 25.8% (to 2024).Profitability 22
- DilutionShare count up 61% since 2020.Capital allocation 18
- Loss-makingLoss of $369.2M over the last 12 months.Fundamentals 31
Its standout strength is valuation, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 31 to 32.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Possible value trap: looks cheap, but score below 50, high risk, weak growth, weak balance sheet.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 27 Sep 2026, revenue fell 4.5% on the twelve months before. Revenue has grown strongly since 2006, at around 19% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 47%, operating −34%, net −41%. Last 12 months: net −14%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Feb 2027in 90 days
- Last reported
- 3 Nov 2026EPS reported $0.31 (expected $0.20)above expectations
Analyst estimates
- Earnings per share
- $0.71−8.1%
- Revenue
- $2.52B−1.0%
- Earnings per share
- $1.38−3.4%
- Revenue
- $2.52B−2.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −29.8%Full-year guidance updated to revenue of $2.52 billion to $2.6 billion, adjusted EBITDA of $540 million to $560 million and adjusted EPS of $0.65 to $0.90; free cash flow guidance withdrawn and a weaker respiratory season expected.
“Turning to profitability, we now expect full-year 2026 adjusted EBITDA of $540 million to $560 million, representing an EBITDA margin range of 21% to 22%. And we now expect adjusted EPS of $0.65 to $0.90.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Strobeck MatthewPurchase
13 Feb 2026, Board
- Shares
- 10,000
- Price
- $23.96
- Value
- $239,586
- Busky Joseph M.Purchase
13 Feb 2026, Chief Financial Officer
- Shares
- 3,370
- Price
- $23.66
- Value
- $79,742
- Blaser Brian J.Purchase
13 Feb 2026, President and CEO
- Shares
- 10,540
- Price
- $23.59
- Value
- $248,661
Show 5 more
- Rhoads Ann DPurchase
10 Dec 2025, Board
- Shares
- 750
- Price
- $28.28
- Value
- $21,206
- Wilkins Joseph D Jr.Purchase
26 Nov 2025, Board
- Shares
- 370
- Price
- $27.96
- Value
- $10,343
- Widder Kenneth JSale
25 Nov 2025, Board
- Shares
- 4,026
- Price
- $27.81
- Value
- $111,965
- Busky Joseph M.Purchase
24 Nov 2025, Chief Financial Officer
- Shares
- 4,770
- Price
- $26.06
- Value
- $124,305
- Polan Mary Lake Ph DPurchase
21 Nov 2025, Board
- Shares
- 1,000
- Price
- $22.43
- Value
- $22,430
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at QuidelOrtho
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- Sysmex6869.T $7.83B70
- Ypsomed HoldingYPSN.SW $6.56B76
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- Mesa LaboratoriesMLAB $782.43M58
- Shoulder InnovationsSI $458.61M48
- Mobia MedicalMOBI $448.43M45
- BrainsWayBWAY $440.87M60
ETFs that hold QuidelOrtho
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.09% | 0.40% | €1.49B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.07% | 0.39% | €1.47B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €944.34M |
Show 5 more
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.05% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 28 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.